Is There a Draft In Here? 21st Century Cures Legislation Stumbles At The Starting Line
This article was originally published in RPM Report
The House Energy & Commerce Committee released its eagerly awaited first draft of potential legislation to improve the climate for innovation in the US. Or did it? The unexpectedly partisan reaction is a sign of how far the process still has to go – but the overall pro-innovation focus is likely to carry through.
You may also be interested in...
Investors remain hyper-sensitive to any threat to pricing flexibility for biotech products. The latest over-reaction – to a renewed call for Medicare “price negotiation” – meant missing some of the more meaningful messages coming from Washington about support for innovation.
Aggressive staffing goals for FDA’s gene and cell therapy review group might not be fully achieved – but the head of CBER believes the new organization is on track to deliver on his high expectations going forward.
Biopharma industry is making some modest headway in quest to change the new US Medicare drug price process to treat drugs and biologics on equal footing. But eliminating the so-called ‘pill penalty’ would not on its own equalize the incentives for small molecule and large molecule R&D.